News articles about Exactech (NASDAQ:EXAC) have been trending positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Exactech earned a news sentiment score of 0.29 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 43.7911404293464 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Exactech (NASDAQ:EXAC) opened at $50.10 on Monday. The firm has a market capitalization of $719.75, a PE ratio of 41.40, a PEG ratio of 4.03 and a beta of 1.02. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. Exactech has a one year low of $23.30 and a one year high of $50.95.

Exactech (NASDAQ:EXAC) last released its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). The business had revenue of $61.40 million during the quarter, compared to the consensus estimate of $61.78 million. Exactech had a return on equity of 7.22% and a net margin of 0.18%. research analysts forecast that Exactech will post 1.29 EPS for the current year.

Several analysts have issued reports on the company. Sidoti lowered Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Robert W. Baird lowered Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research note on Monday, October 23rd. Zacks Investment Research lowered Exactech from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Gabelli lowered Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Finally, ValuEngine lowered Exactech from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. Exactech currently has an average rating of “Hold” and an average price target of $49.00.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Insider Buying and Selling by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with's FREE daily email newsletter.